NDANASALSPRAY
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
4/8 — Partial
CARDAMYST (etripamil) by Milestone Pharmaceuticals is l-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDAMYST (etripamil) is a nasal spray L-type calcium channel inhibitor approved by the FDA in December 2025 for the acute treatment of paroxysmal supraventricular tachycardia (PSVT). It works by blocking calcium influx across AV nodal cells and arterial smooth muscle, interrupting reentry pathways to restore sinus rhythm. This represents a novel non-intravenous option for acute arrhythmia management.
Launch16.1 years to LOE
As a newly launched product with no established competitors, CARDAMYST presents significant growth opportunity for commercial teams building market presence and capturing market share in acute arrhythmia care.
Mechanism of Action
L-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). Etripamil exerts its pharmacologic effect by modulating the influx of ionic calcium across the cell membrane of the AV nodal cells as well as arterial smooth muscles and contractile myocardial cells. By interrupting…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
Started Jan 2027
750 enrolled
Atrial Fibrillation
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
Started Dec 2023
60 enrolled
Paroxysmal Supraventricular Tachycardia
A Study of Etripamil in Healthy Subjects
Started Mar 2023
12 enrolled
Healthy Chinese Subjects
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Started Jun 2022
500 enrolled
Tachycardia, SupraventricularParoxysmal Supraventricular Tachycardia
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Started Dec 2021
130 enrolled
Paroxysmal Supraventricular Tachycardia
Worked on CARDAMYST at Milestone Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.